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Structure-based virtual screening of NCI Diversity set II compounds was performed to indentify novel inhibitor scaﬀolds of
trypanothionereductase(TR)fromLeishmaniainfantum.Thetop50rankedhitswereclusteredusingtheAuPoSOMtool.Majority
of the top-ranked compounds were Tricyclic. Clustering of hits yielded four major clusters each comprising varying number of
subclusters diﬀering in their mode of binding and orientation in the active site. Moreover, for the ﬁrst time, we report selected
alkaloids and dibenzothiazepines as inhibitors of Leishmania infantum TR. The mode of binding observed among the clusters also
potentiates the probable in vitro inhibition kinetics and aids in deﬁning key interaction which might contribute to the inhibition
of enzymatic reduction of T[S] 2. The method provides scope for automation and integration into the virtual screening process
employing docking softwares, for clustering the small molecule inhibitors based upon protein-ligand interactions.
1.Introduction
Leishmaniasis is a protozoan disease caused by the parasite
belonging to the genus Leishmania; the disease belongs to
group of neglected tropical diseases as deﬁned by World
Health Organization. The disease is caused by 20 diﬀerent
species belonging to the genus Leishmania. The causative
species of visceral leishmaniasis (VL) include Leishmania do-
novani, Leishmania infantum in Asia, Africa, and Europe
(Old World), and Leishmania chagasi in South America
(New World) [1–4]. Trypanothione metabolisms involving
various enzymes including Trypanothione reductase which
has been ideal target for designing chemotherapeutics [5–7].
TheabsenceofTRinhumansmakesitanattractivetargetfor
rational drug design towards Leishmaniasis.
Onlyaverylimitednumberofdrugshavebeendeveloped
forthe treatment of Leishmaniasis over the past 60 years, and
the use of available drugs has been hampered by high cost,
adversesideeﬀects,developmentofresistancebytheparasite,
andalsotheeﬃcacy[8].Someexperimentalaswellasinsilico
attempts have been made to identify inhibitors or subversive
substrates of TR [9, 10]. TR is a homodimer, and the active
site residues are contributed by both the chains, and docking
and crystalisation studies on TR of Trypanosoma cruzi with
tricyclic compounds has shown that they bind to the hydro-
phobic wall on active site formed by Trp21 and Met113
[11, 12], but in case of Leishmania infantum, trypanothione
reductase docking studies show that it binds to the hydro-
phobic region formed by Phe396, Leu399, and Pro462 [13].
TR active site is negatively charged with surrounding hy-
drophobic residues, while GR of mammalian counterpart is
positively charged. Thus, a typical speciﬁc inhibitor of TR
s h o u l dh a v ea ne x t e n d e dh y d r o p h o b i cr e g i o na n da no v e r a l l
positive charge, where charge plays a major role in binding
of the inhibitor to the active site and also in discrimination
between a TR and GR inhibitor [14]. The additional hydro-
phobic region present in proximity of the active site was
formed by residues Phe396, Pro398, and Leu399. The con-
servative substitution of these in TR by Met406, Tyr407,
Ala409inhumanGRandcanberationallyexploredtodesign
inhibitors speciﬁc towards parasite TR.
There is an urgent need for eﬃcient antileishmanial
chemotherapeutic agents, with the advent of automated
computational techniques; we aim to identify novel TR in-
hibitorswhichcanbepotentialantileishmanialagents.Struc-
ture based drug design (SBDD) has gained importance over2 The Scientiﬁc World Journal
the last few years, due to its potential to identify novel lead
compounds in the drug designing process. SBDD comprises
two broad computational categories, they are based upon the
protein-ligand interactions, ligand similarity searches [10].
Methods using protein-ligand interactions employ docking
in their screening process, and pharmacophore generation
is performed in case of ligand similarity searches. Virtual
screening of small molecule databases is now a well-estab-
lished protocol for identiﬁcation of potential lead com-
pounds in the drug designing process, provided the three-
dimensional structure of the protein is known. Structure-
based virtual screening approach is primarily applied as a
hit identiﬁcation tool and also used in lead optimization; the
aim is to reduce a large number of compounds to a smaller
subsetwhichcanbebiologicallyactiveagainstthetarget.The
process of virtual screening to design inhibitors towards an
enzyme involves modeling of the binding site of the inhibitor
at the active site of the enzyme through docking procedures
and scoring, ranking of those compounds to narrow down to
a smaller subset which contains potential biologically active
inhibitors [15, 16].
In our study, NCI Diversity set II was used as small
molecule chemical library owing to the diversity of chemical
entities present in the set, and for small molecule conforma-
tional search AutoDock4 [17], molecular docking program
was performed. Based upon the binding energies, the highest
ranked structures from the docking program were clustered
to ligand-foot-print the interactions of diverse compound
sets aiding in classiﬁcation of diﬀerential binding modes ex-
hibited by small molecules at the active site of TR. The inter-
actions were clustered from protein-ligand complexes using
AuPosSOM [18], and they were also classiﬁed into sub-
groups. Four diﬀerent major clusters were obtained based
upon the interaction of inhibitors on the active site of TR;
each cluster exhibiting diﬀerences in the mode of binding
and subclusters within clusters showed conservation in their
binding pattern. The inhibitors bind primarily to the hydro-
phobic stretch formed by Leu399 which is in close proximity
to the active site commonly known as the Z-site. In silico
studies on other drug targets proteins are also ongoing in our
laboratory [19].
2. Methods
2.1. NCI Diversity Set II. The National Cancer Institute Di-
versity set II (http://dtp.nci.nih.gov/branches/dscb/diversity
explanation.html) is a structural database selected from NCI
chemical library. The webpage also provides details of com-
pounds like molecular weight and so forth; 2D SDF data set
ofthecompoundsavailableonlinewasdownloadedandused
for generation of three dimensional structure coordinates
of small molecules using ChemDraw 3D ultra 8.0 software
(Molecular Modelling and analysis; Cambridge soft Corpo-
ration, USA (2003)).
2.2. Ligand and Protein Preparation. The NCI Diversity set
II 2D SDF ﬁles were obtained, they were submitted to
Online SMILES Translator to obtain three dimensional co-
ordinates, the multi-PDB ﬁle was split and converted into
PDBQT format, input format for AutoDock4.The charges
on the ligand atoms were preserved, nonpolar hydrogens
were merged, default rotatable bonds were retained using
TORSDOF utility [20]. The crystal structure of Leishmania
infantum TR (PDB ID: 2JK6) resolved at 2.95 ˚ Aw a sr etri ev ed
from the Protein Data Bank [21]. Aﬃnity grids of size 80 ×
80 × 80 ˚ A with 0.200 ˚ A grid spacing around the active site,
aﬃnity grid maps were generated for each of the atom types
present in the protein and all possible atom types (HD, C, A,
N, NA, OA, F, P, SA, S, Cl, Br, and I) in the NCI Diversity
set II. An electrostatic and a desolvation grid map were also
generated.
2.3. Docking. Docking simulations were performed as de-
scribed earlier using Lamarckian genetic algorithm (LGA)
[13]. LGA is a hybrid of genetic algorithm, and local search
algorithm the other two algorithms available with Auto-
Dock4 [16, 22, 23].
The active site of TR was kept rigid, and nonﬂexible
docking was carried out. The docking parameters for the vir-
tual screening process were set to default with the exception
of the following: trials of 20 Lamarckian Genetic Algorithm
runs with each case (ga run, 20), initial population size of
300(ga pop size,300),randomstartingpositionandconfor-
mation, and 250,000 (ga num evals, 250,000) energy evalua-
tions.Eachdockingsimulationproduced20diﬀerentdocked
conformations, which were then clustered based upon Root-
Mean-SquareDeviation(RMSD)ofthediﬀerentboundcon-
formations; the RMSD diﬀerence between conformations
within each cluster will be less than 2 ˚ A. The binding energy
of each cluster is the mean binding energy of all the confor-
mations present within the cluster; the cluster with lowest
binding energy and higher number of conformations within
it was selected as the docked pose of that particular ligand.
2.4. Preparation of Protein-Ligand Complexes and Clustering.
Protein-ligand complexes were written for the top-ranked
compounds obtained after sorting the results obtained from
the multiple docking simulations; they were sorted based
upon their binding energy and also on the basis of number
ofconformationspercluster.Clusteringoftheprotein-ligand
complexeswasperformedtoclassifytheprotein-ligandinter-
action; AuPosSOM (Automatic analysis of poses using SOM)
was used for this purpose [18]. The clustering of the protein-
ligand complexes is primarily carried out in three steps. A
self-organisingmap(KohonenSOM)trainingisinitiallyper-
formed to deﬁne protein-ligand contact descriptors, based
upon the ligand interaction footprints, the complexes are
clustered, and for visualisation purpose, a Newick tree ﬁle is
generated. Interleaved vectors are generated for all the atoms
in the protein-ligand complexes. Vector generation is done
using BioPython scripts; this takes into consideration both
bonding and non-bonding interactions possible in the pro-
tein-ligand complex. The generated are then trained using
Kohenen’s self-organising maps; the trained vectors are then
clustered. The SOM generate was used for construction of
Newick tree, which was prepared using Dendroscope. Fig-
ures showing bonding and nonbonding interactions wereThe Scientiﬁc World Journal 3
Table 1: Structure and docking statistics of top 50 ranked structures. C, CL, E, A, and T indicate numbers of clusters, number of conforma-
tions within the selected cluster, binding energy of the selected conformation in kcal/mol, number of atoms in the inhibitor, and number of
torsions, respectively.
Compound NSC ID C CL E A T
1
O
O
O O
59620 6 10 −10.22 30 2
2
HO
N
H
60785 10 9 −10.09 29 1
3 N HO 170955 8 8 −9.76 23 1
4 N N
N
S
O
O
Cl
H2N
NH2
NH2
117268 8 8 −9.75 31 4
5
N
OH
H
N
332670 12 6 −9.64 26 2
6
N
N
O
O 163443 16 4 −9.51 30 5
7
O
O
O
O
HO
OH OH
OH
OH OH
345647 19 2 −9.46 46 7
8
O
HO
NH
27592 6 6 −9.44 32 1
9
N
N N
O
O NH
NH
359472 10 5 −9.4 29 4
10
O
N
N
25457 12 4 −9.36 27 3
11 N
N
N
NO O NH
Cl
338963 13 3 −9.35 31 44 The Scientiﬁc World Journal
Table 1: Continued.
Compound NSC ID C CL E A T
12
O
N
N
116702 10 7 −9.34 28 3
13
O
O
O
O
219894 20 1 −9.34 30 6
14 N
N
N
N
NH
NH Br
Br
11667 11 5 −9.28 28 3
15 N
O
O
N
H
105781 11 5 −9.21 24 2
16
N
N
O
O
O
O
NH
H2N
OH
639174 15 3 −9.18 35 5
17
O
N
O
O−
N+
24951 5 16 −9.11 26 0
18
N
O
O 116709 16 3 −9.09 27 4
19
N
S
O
O
N
Cl
321491 12 4 −9.07 26 3
20
N
F
F
F
HO
H
N
82802 4 15 −9.05 31 3
21 N N O
HO Cl
91396 20 1 −9.04 29 7The Scientiﬁc World Journal 5
Table 1: Continued.
Compound NSC ID C CL E A T
22
O
O
O
NH
Br
292923 8 8 −9.04 24 2
23
N
NH
S
Cl O
309874 16 3 −9.02 32 4
24
N
N N
H
N
N
O
H2N
11826 7 7 −92 3 1
25
O
S
O O
NH HN 3752 9 7 −8.99 23 3
26
N N
O O
HN NH
37553 20 1 −8.99 38 4
27
OO
670283 5 12 −8.99 27 0
28
N
N
N S
327702 13 4 −8.97 26 3
29
N
NH
N
H
HN 81462 1 20 −8.96 16 0
30 N
N
N N
Cl NH HN
Cl
11668 12 5 −8.95 28 3
31
N
N
N
N
N
N
NH2
NH2N
H2N 4429 13 4 −8.94 30 2
32
NH NH
N
H
632536 13 3 −8.94 27 46 The Scientiﬁc World Journal
Table 1: Continued.
Compound NSC ID C CL E A T
33
O
O
NH
HO
OH
156565 10 9 −8.92 30 6
34 N
N
O
NH 39352 9 8 −8.89 23 2
35
N
N
N
NH2
345845 11 5 −8.87 30 2
36
O N
N
H   OH OH
372499 8 13 −8.87 26 3
37
S
N
S
O
O
F
Cl
158413 17 2 −8.86 28 4
38
O
O
O
NH
96021 12 6 −8.81 34 2
39
N N O
OH
Cl
111210 18 2 −8.79 29 7
40
N
O
NH
Cl
Br
Cl
Br
379880 16 2 −8.79 27 3
41
O
N
N
O
O
O
308835 18 2 −8.78 36 3
42
OH
21603 6 8 −8.72 22 1
43
F
F
F
N
N
N
N
O
O
N
F
F
F
328101 19 2 −8.68 37 6
44
S
N
O O
N
H
5476 12 5 −8.66 24 2The Scientiﬁc World Journal 7
Table 1: Continued.
Compound NSC ID C CL E A T
45
O
O
O
O
16437 20 1 −8.66 28 6
46
N
N
N
O
96996 15 2 −8.63 26 3
47
ON
N
N
O
80313 7 7 −8.62 25 1
48
O
O
N
H
H
N
84100 13 3 −8.61 32 3
49
N
OH
Cl
H
N
13316 16 4 −8.59 27 4
50
S
O
N
O H2N Cl
159092 8 11 −8.56 24 4
prepared using LIGPLOT program [23]; ﬁgures graphically
representing the mode of interaction were prepared using
UCSF Chimera.
3. Result andDiscussion
The results obtained from the virtual screening process were
sorted, and they were ranked based upon their binding ener-
gy; from the diversity set, top 50 ranked structures were used
for further clustering analysis (Table 1), and the criteria set
toidentifythebindingposewerelowestbindingenergy,max-
imum number of conformations in the cluster. Clustering
was performed downstream of virtual screening to classify
the inhibitor scaﬀolds by contact-based analysis, clustering
with AuPosSOM gave four diﬀerent major clusters and each
major cluster had subclusters except Cluster 3 (Figure 1).
Each major signiﬁes a diﬀerential binding mode of com-
pounds conﬁned within that cluster; both hydrogen bonding
and non-bonding interaction were taken into consideration
for contact-based clustering of protein-ligand complexes.
A donor hydrogen list and acceptor list is generated by
AuPosSOM to calculate potential hydrogen bonds, when a
hydrogenbonddonorandanacceptorarepresentwithin3 ˚ A,
then it is taken into consideration as a hydrogen bond. As
listed in Table 2, protein-ligand interactions within a cluster
were greatly conserved, whereas sub clusters within each
cluster showed slight degree of variation in the observed
mode of interaction (Figure 2).
3.1.InteractionofCompoundswithConventionalHydrophobic
Patch of Active Site. In cluster 1, the ligands traverse the
active site region and have hydrogen bonding potentials with
amino acids of both conventional hydrophobic wall and also
the Z site residues. The cluster contained two sub-clusters
(SC) with eight (SC-1) and three (SC-2) in each. Inhibitors
belonging to this cluster are in hydrophobic interaction with
amino acids such as Tyr110, Trp21, Glu18, and Met113,
where Tyr110 is a key residue aiding in anchoring of T[S]2
towards the hydride transfer region, Glu18 provides a nega-
tive charge to the active site, and Trp21 and Met113 form
a nonpolar patch in the substrate-binding site of TR where
spermidine moiety of T[S]2 would be located in the rest of8 The Scientiﬁc World Journal
1
Cluster 1
Cluster 2
Cluster 3
Cluster 4
Figure 1: Cluster tree showing four major clusters (Cluster 1, Cluster 2, Cluster 3, and Cluster 4), each cluster signiﬁes a diﬀerent ligand
footprint on the protein-ligand complex. The protein-ligand interactions within the cluster are conserved; they vary between the clusters.
The subclusters within a cluster also show similar interaction modes with slight variation in the binding pattern.
(a) (b)
(c) (d)
Figure 2: Orientation of inhibitors segregated into four diﬀerent clusters at the active site of TR. Inhibitors in Cluster 1 (a) position
themselvesbetweenboththehydrophobicpatchesoftheactivesite,Cluster2(b)bindtotheZsitewiththeirsidechainsorientingthemselves
towards the negatively charged residues of the active site. In Cluster 3 (c), the ligands primarily bind to the negatively charged residues such
as Glu466, Glu467 residues involved in orientation of active site histidine during hydride transfer process, in Cluster 4 (d) comprise of
compounds which stack to the Z site, in the vicinity of the active site and they also interact with Lys61 of the substrate-binding site.The Scientiﬁc World Journal 9
Table 2: Table showing conserved interaction of ligands with active site residues of TR within clusters.
S. no. Cluster Compounds present in the cluster∗ Conserved interaction within the cluster
(bonding and nonbonding interactions)
1C l u s t e r 1 SC-1 [Cpd3, Cpd8, Cpd9, Cpd16, Cpd38, Cpd43] Leu399, Ser14, Glu18, Trp21, Tyr110,
Met113, Cys52 SC-2 [Cpd5, Cpd21, Cpd25]
2C l u s t e r 2
SC-3[Cpd7, Cpd17, Cpd20, Cpd26, Cpd40, Cpd42]
His461, Leu399, Thr65, Glu466, Pro398,
Thr396, Phe396, Pro398
SC-4[Cpd2, Cpd15]
SC-5[Cpd24, Cpd37, Cpd48]
SC-6[Cpd6,Cpd23]
3 Cluster 3 SC-7[Cpd14, Cpd29, Cpd30, Cpd31, Cpd49, Cpd32] Glu466, Glu467, Thr463, Ser394
4 Cluster 4 SC-8[Cpd10, Cpd44, Cpd50] Leu399, Pro398, Phe396,
SC-9[Cpd12, Cpd19, Cpd27, Cpd28, Cpd33, Cpd34,
Cpd36, Cpd46, Cpd47] Met400, Lys61
SC-10[Cpd22, Cpd45]
SC-11[Cpd1, Cpd4, Cpd11, Cpd13, Cpd18, Cpd39, Cpd41]
SC-12[Cpd35]
∗[] subclusters (SC) within major clusters are separated using [].
the amino acids which are in hydrophobic interaction to the
core of the conventional hydrophobic wall providing sub-
strate speciﬁcity to the TR active site. Compound 21 of
SC-2 produced 20 diﬀerent conformations out of genetic
algorithm runs performed, which can be attributed to the
higher number of torsions in the ligand, making it a diverse
binding compound.
In SC-1 Compound 16 (Figure 3(a))f o r m e dh y d r o g e n
bondingwithTyr110andGlu18whicharekeyresiduesinthe
active site providing substrate speciﬁcity and anchoring sub-
strate to the active site, respectively; as a conserved pattern
among the cluster 1 compounds, this compound also had
hydrophobic interactions with residues of both Z-site and
amino acids providing net negative charge key for lodging of
T[S]2 to the active site. The higher aﬃnity of this compound
totheactivesitewasduetohydrophobicinteractionofitwith
hydrophobic patch formed by Trp21, Met113, and Cys52,
His461 (active site histidine base) of the hydride transfer
region, whereas Compound 38 (Figure 4(a)) had hydropho-
bic interaction with all the residues in the core hydrophobic
patch of the active site. Most compounds present within this
clusterwerelinearpentacycliccompounds occupying ahigh-
er steric space in the active site and thus potentially can
inhibit the reduction of T[S]2 by competing for active site
binding region. Compound8, an alkaloid named tomatidine
(anaturalcompoundfromSolanumSpp),alsoshowedinter-
actions of a potential inhibitor with the same hydrophobic
and hydrogen bonding interactions that are observed within
this cluster, potentiating them as scaﬀolds to study as inhib-
itors of TR. In SC-2, the conserved pattern was along with
hydrophobic interactions with that of the conventional
hydrophobic patch, but the cyclic structures also bind to
the negatively charged region in the active site comprising
Glu466,Glu467,andCompound5belongingtothissubclus-
ter formed hydrogen bonding with Lys61 which is in close
proximity to the active site.
3.2. Binding of Inhibitors in Vicinity of Hydride Transfer Re-
gion. Incluster2,therewerefoursub-clusters(SC3-SC6),the
conserved interaction observed among this cluster was the
inhibitors are in hydrophobic interaction with amino acids
His46,Thr65,andtheZsiteresidues,whereHis461formsthe
core of the hydride transfer region along with Cys52, Cys57.
The inhibitors belonging to this cluster may potentially
inhibit the reduction of T[S]2, by disrupting the hydride
transfer from His461 to FAD of the active site and then
to active site Cystines, by being in hydrophobic interaction
and hydrogen bonding interaction with the key residues
of hydride transfer process. Diﬀerent bound conformation
w a sa t t a i n e dw i t he v e r yr u ni nc a s eo fCompound 26 and
Compound 7 in SC-3, making them a diﬀerentially binding
compound with an RMSD of more than 2 ˚ Ab e t w e e ne a c h
bound conformation generated by the docking process.
As representative from this cluster, the binding of
Compound48(Figure 4(a))belongingSC-5totheactivesite
is depicted in Figure 3(b). The compound binds to the active
site having hydrophobic interactions with residues from the
Z site hydrophobic patch and also having hydrogen bond
formingpotentialswithresiduesinvolvedinhydridetransfer;
this was the conserved mode of interaction observed within
this sub-cluster, in case of Compound 20 of SC-3 (Figure
4(b)), the compound formed hydrogen bonds with Thr397
andThr65whichareinvicinityoftheactivesiteresidues.The
cyclic structures of the compound stack themselves between
the hydrophobic patch formed by the Z-site residues and the
negatively charged region comprising Glu466 and Glu467.
3.3. Interaction of Inhibitors with Glu466, Glu467 of the Active
Site. All the ﬁve inhibitors present in this cluster had hy-
drogen bonding potentials with Glu466 and Glu467; these
residues form hydrogen bonds with of active site histidine
(His461)orientingthesidechaintowardsthehydridetransfer
site for reduction of T[S]2. Primarily, binding of inhibitors to
this region is because of charge-based interaction, and they
also have hydrophobic interactions with serine residues sur-
rounding the active site making this conformation a highly
favourable binding energy interaction. Inhibitors belonging10 The Scientiﬁc World Journal
(a) (b)
Figure 3: Compound 16 (a) of cluster 1 traversed between hydrophobic patches formed by Trp21, Met114 and Leu399, Pro492, and Pro398
where later is located in vicinity to the substrate-binding site, it also showed hydrogen bonding potential with Tyr110 of the active site,
Tyr110 anchors the substrate to the active site by hydrogen bonding with the spermidine moiety. Compound 48 (b) of Cluster 2 binds to
the Z site with hydrogen bonding potentials with His461, active site histidine base, and also with the residues which aid in orientation of
substrate towards the active site.
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Figure 4: Ligplot showing proposed hydrogen bonding and non bonding interaction of Compound 38 (a) and Compound 20 (b) from
Cluster 1, Cluster 2, respectively. They bind to the active site with speciﬁc interaction pattern representation of each cluster. Compound 38
stacks itself between two hydrophobic patches in the active site, whereas compound 20 is in nonbonding interaction with Z site residues and
Glu of active site.The Scientiﬁc World Journal 11
(a) (b)
Figure 5: Binding Compound 31 (a) at the active site, the compound is lodged at the periphery of the active site, with potential hydrogen
bonding interactions with Glu4666 and Glu467 making it a high-aﬃnity interaction. Compound 47 (b) belonging to Cluster 4 binds to the
additional hydrophobic patch with side chains extending towards the substrate-binding cleft.
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Figure 6: Compound 30 (a) of Cluster 3 in hydrogen bonding interaction with Glu466, Glu467, Thr463, Pro398, and Phe396 of the Z site is
in hydrophobic contact with the inhibitor. Compound 35 (b) is in hydrophobic interaction with all the Z site residues, and there are other
amino acids in non-boding interactions making it a high-aﬃnity binding.
tothisclustercanbepotentialinhibitorsofTR,bypreventing
the hydride transfer between T[S]2 and active site histidine.
Compound 31 (Figure 5(a))a n dCompound 30 (Figure
6(a)) in the cluster exhibit the conserved interaction pattern
observed within SC-7; we hereby propose that charge-based
interaction at this region with tricyclic moieties being lodged
at the Z site can be developed as a rational ploy to selective
inhibitors of TR.
3.4. Diﬀerential Binding Modes Exhibited by the Inhibitors at
the Z Site. Cluster 4 comprises of larger number of confor-
mations than any other cluster obtained through the self-
organizing maps, ﬁve diﬀerent sub-clusters were observed
within the major cluster, the larger class of compounds
present in this cluster are tricyclic compounds ranging from
acridines to thiazenes, and few halogenated compounds. The
higher aﬃnity of tricyclic structures to the Z site amino acid12 The Scientiﬁc World Journal
residuesandtheirfavorablehydrophobicinteractionwiththe
inhibitors makes it a larger cluster, residues that are in con-
servedinteractionwithinthisclusterareLeu399,Pro398,and
Phe396. Where Leu399 is a conservative substitution from
GR among TR of all the Trypanosomatids, this additional
hydrophobic region present in the vicinity of the substrate-
binding site helps in stacking of tricyclic compounds, being
the major class of inhibitor reports against TR. The side
chainsofinhibitorsareinhydrogenbondingornon-bonding
interaction with the residues of substrate-binding site.
In case of Compound 1 (SC-11), the inhibitor is in non
bonding interaction with all the Z site residues and 10 other
amino acids surrounding the active site; the stacking of pen-
tacyclic structure between the hydrophobic patches makes it
a highly favorable binding energy compound, no hydrogen
bonding interaction was observed between the active site re-
sidues and this compound. Compound 47 (SC-9) (Figure
5(b)) forms hydrogen bond with Thr463 of the active site,
the tricyclic moiety of the compounds is docked against the
hydrophobic patch of Z site and the side chains are extended
towards the substrate-binding cleft. Compound 35 (Figure
6(b)) of SC-12, the single compound that was present in the
subcluster, is in hydrophobic contact with Met400, Val58
and in charge-based interaction with Lys61 of the substrate-
binding cleft along with conserved interaction of Cluster 4.
The additional hydrophobic patch formed by the conserved
substitution of Leu399 in TR of all Trypanosomatids can be
utilized for selective designing of inhibitors towards the en-
zyme. Polycyclic compounds (tricyclic and pentacyclic) were
found to have higher aﬃnity towards the Z site; the proto-
nated side chains of these classes of compounds can interfere
with the binding of substrate to the active site by being in hy-
drogen bonding or non-bonding interactions with residues
of substrate binding cleft, thereby inhibiting the reaction.
Theresultsshowdiversemoleculesetsbindingwithhigh-
er aﬃnity to the active site of TR in four diﬀerent conforma-
tions. In cluster 1, inhibitors are stacked between the two hy-
drophobic patches cluster 2 contains inhibitors which bind
to the active in site an orientation which facilitates it to be
in hydrogen bonding interaction with Z site amino acids and
the protonated side chains to be in charge-based interaction
with negatively charged region of the active site. Whereas in
cluster 3 hydrogen bonding of inhibitors with Glu466 and
Glu467 was observed and in cluster 4 inhibitors bind with
higher aﬃnity to the Z site, facilitated by hydrogen bonding
andnon-bonding interaction withsurrounding aminoacids.
Although the active site of TR is comparatively larger when
compared to active site of GR and small molecules bind to
the active site in multiple orientations by clustering, it was
evidenttheinteractionsareconﬁnedtofourdiﬀerentregions
in the active site, and more than one molecule of inhibitor
can bind to the active site due to the multiple binding modes
possible for any given inhibitor. We for the ﬁrst time report
selective inhibitors can be designed towards TR by combin-
ing the hydrophobic interaction of inhibitors with conserv-
ed Leu399 substitution and surrounding amino acids with
charge-based interaction of Glu466 and Glu467 which can
result in disruption of in vitro enzymatic conversion of T[S]2
to T[SH]2 by preventing the hydride transfer, the residues
facilitatetheorientationofHis461towardsthehydridetrans-
fer region by hydrogen bonding to active site Histidine.
Thehitsrepresentativeofeachclustercanbeusedforfur-
ther development of speciﬁc inhibitors, and diverse binding
modes explored by the method can be used for pharmaco-
phore mapping in the process of designing more potent in-
hibitors against TR. The in vitro kinetics of each cluster vary
depending upon their binding pattern, and contact based
analysis of large chemical libraries can be performed to de-
crease the number of false positive hits obtained through the
virtual screening process. For this purpose, true positive and
false positive sets can be integrated into the virtual screening
process.
The modeled binding modes provide insight into possi-
blemodeofbinding thatdiversesetofcompoundscanattain
at the active site of TR. Similar methodology can also be
employed for other inhibitor screening processes, where
contact-based ligand footprinting can be employed to dis-
criminate between true positives and false positives. The
screening process can also be supplemented with enzyme
kineticassaystovalidatetruehits,whichcanbefurthermod-
iﬁed for development into potential leads and drugs. Similar
studies on the other enzymes of redox metabolism may be
valuable towards novel drug discovery against leishmaniasis
[24].
4. Conclusions
We report that alkaloid tomatidine and also few other diben-
zothiaphenes, acridines can be potential inhibitors of TR.
The diﬀerential binding mode of small molecules at the ac-
tive site of TR has been clustered into four major clusters
based upon ligand footprinting. The clusters have conserved
interaction with Z site amino acids among them either as
non-bonding interaction or hydrogen bonding interaction,
reiterating the fact that this conservative substitution can
be utilized for development of selective inhibitors towards
TR. Some of the inhibitors here show that along with the
chemical nature of the compounds net charge on the com-
pound also plays a critical role in binding to the active site
and also providing speciﬁcity towards TR. Binding strength
of inhibitors and in vitro kinetics is dependent upon aﬃnity
and interaction of inhibitors towards the active site, so
a contact-based clustering approach to classify inhibitors
would provide eﬀective segregation of diﬀerent classes of in-
hibitors for a particular protein. The above-discussed meth-
od can be eﬀectively used downstream of virtual screening
processes or in combination with docking protocols to dis-
criminate between diﬀerent interaction patterns observed
within a chemical library.
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